INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced

Key Takeaways Insmed posted preliminary FY25 revenues of $606.4M, topping forecasts on Arikayce and Brinsupri sales.Brinsupri delivered $172.7M in 2025 sales, with $144.6M generated in Q4, its first full launch quarter.Outlines 2026 plans, including Arikayce guidance, ENCORE data timing and multiple phase III TPIP studies.Shares of Insmed (INSM) gained more than 3% on Friday after the company reported preliminary sales numbers for full-year 2025. It also outlined some expected milestones related to its comm ...